HIV Therapy
FDA Approves Viread
Published in AIDS Weekly, December 3rd, 2001
Gilead Sciences (GILD) has received U.S. Food and Drug Administration (FDA) approval for its antiretroviral agent Viread (tenofovir disoproxil fumarate) for the treatment of human immunodeficiency virus (HIV) infection when taken in combination with other antiretroviral agents. The approval comes six months after Gilead submitted the Viread New Drug Application (NDA) to the FDA. Viread is given as one 300 mg tablet once daily with a meal.
"Viread addresses many of the needs of people living with HIV today. The drug has demonstrated a significant antiviral response, even in patients who may no longer respond well to available therapies due to the development of viral...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2001-12-03)
More Articles from AIDS Weekly
- AIDS And HIV Therapy
Novel Technique Developed For Measuring Antiretroviral Toxicity - HIV Vaccine
Subtype C SHIV Variant May Be Useful In African Vaccine Development - HIV Therapies
Papers Add New Knowledge On HIV's Infection Tactics - Reproductive Medicine
Pokeweed Protein Semen Treatment May Enable Safe Insemination From HIV Patients - AIDS And HIV Therapy
Enteric-Coated Didanosine Linked To Milder Gastrointestinal Effects - Epidemiology
China Confronts Growing AIDS Problem At First National Conference - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
